In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Is metabolically healthy obesity indeed healthy at the microvascular level?

Session Risk Factors and Prevention ePosters

Speaker Eduardo Tibirica

Event : ESC Congress 2020

  • Topic : preventive cardiology
  • Sub-topic : Obesity
  • Session type : ePosters

Authors : E Tibirica (Rio de Janeiro,BR), G Huguenin (Rio de Janeiro,BR), L Rodrigues-Junior (Rio de Janeiro,BR), D Pecanha (Rio de Janeiro,BR), M Duque (Rio de Janeiro,BR), S Escobar (Rio de Janeiro,BR), A Duque (Rio de Janeiro,BR), M Mediano (Rio de Janeiro,BR), C Araujo (Rio de Janeiro,BR), A Lorenzo (Rio de Janeiro,BR)

Authors:
E Tibirica1 , G Huguenin1 , L Rodrigues-Junior1 , D Pecanha1 , M Duque1 , S Escobar1 , A Duque1 , C Araujo1 , M Mediano1 , A Lorenzo1 , 1National Institute of Cardiology - Rio de Janeiro - Brazil ,

Citation:

Background:
In the current "obesity epidemic", obese individuals without insulin resistance, lipid disorders, or hypertension, have been called "metabolically healthy" (MHO) and considered to have intermediate cardiovascular risk, between that of healthy nonobese (HNO) individuals and of metabolically unhealthy obese (MUO). Nonetheless, this is controversial, as MHO may have subclinical abnormalities, and indeed may be a transitory state in the way to the unhealthy phenotype.

Purpose:
To evaluate systemic microvascular reactivity in MHO, MUO and HNO.

Methods:
Ten MHO, 10 MUO and 20 HNO individuals were studied. Obesity was considered as a BMI≥30 kg/m2. The NCEP/ATPIII criteria, excluding waist circumference, were used to define the metabolically healthy phenotype (absence of all criteria) or unhealthy phenotype (presence of any of the criteria). Laser speckle contrast imaging coupled with skin acetylcholine (Ach) iontophoresis was employed to study cutaneous microvascular reactivity (endothelial-dependent vasodilatation), as a surrogate for systemic microvascular function, and cutaneous vascular conductance [CVC in arbitrary perfusion units of microvascular flow (APU)/mean arterial pressure (mmHg)] was measured.

Results:
Mean age was 34.8, 36.7 and 32.3 years (P=0.17, ANOVA) and BMI was 20.7, 32.2 and 33.3 kg/m2 (P<0.0001) for HNO, MHO and MUO, respectively. Both MHO and MUO had significantly decreased microvascular vasodilation in comparison to HNO (Figure). Of note, there was no significant difference between MHO and MUO regarding CVC (both similarly decreased when compared to the healthy controls).

Conclusions:
This study underscores that MHO is not a "benign" condition, as it has adverse effects on microvascular function, similarly to those found in MUO. The study of cutaneous microvascular function may be useful to identify subclinical abnormalities in obese individuals who might deserve more intensive management.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are